Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.50 |
| ▸ | DPP4 | P27487 | 4/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.42 |
| ▸ | KDM5A | P29375 | 1/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.41 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.41 |
| ▸ | DHODH | Q02127 | 10/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.38 |
| ▸ | EIF4E | P06730 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25939425 | 0.89 | DPP4 (0.49) | MCL1DPP4DPP8 | |
| SCHEMBL25939429 | 0.89 | DHODH (0.46) | MCL1DPP4DPP8DHODHPTPN1 | |
| SCHEMBL25939500 | 0.84 | DPP4 (0.47) | MCL1DPP4DPP8DHODHPTPN1 | |
| SCHEMBL29717631 | 0.81 | MCL1 (0.50) | MCL1KDM5AKDM4CKDM5BDHODH | |
| SCHEMBL25939449 | 0.81 | MCL1 (0.50) | MCL1DPP4KDM5AKDM4CKDM5B | |
| SCHEMBL15973746 | 0.81 | MCL1 (0.50) | MCL1KDM5AKDM4CKDM5BDHODH | |
| SCHEMBL25939516 | 0.80 | DHODH (0.58) | DPP4DHODH | |
| SCHEMBL25939456 | 0.80 | DHODH (0.52) | DHODH | |
| SCHEMBL25939538 | 0.78 | DPP4 (0.42) | MCL1DPP4DPP8KDM4CDHODH | |
| SCHEMBL15973841 | 0.77 | MCL1 (0.51) | MCL1KDM5AKDM4CKDM5BDHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285365-A1 | USE OF A DHODH INHIBITOR COMPOUND IN COMBINATION CANCER THERAPY | SERVIER PHARMACEUTICALS LLC (US) | 2023-09-14 | — | — | US | disclosed |
| US-11717512-B2 | Methods of use for trisubstituted benzotriazole derivatives | SERVIER PHARMACEUTICALS LLC (US) | 2023-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11717512-B2 | Methods of use for trisubstituted benzotriazole derivatives | BRDT, BRPF3, BRD4 | MCL1 52/4885DPP4 2193/4885DPP8 2932/4885 |
| US-20230285365-A1 | USE OF A DHODH INHIBITOR COMPOUND IN COMBINATION CANCER THERAPY | DHODH, DHRS9, DLD | MCL1 28/4885DPP4 1623/4885DPP8 1968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.